Edema of the face and extremities secondary to pemetrexed.

Pemetrexed is an anti-folate chemotherapy first approved in 2004 by the Food and Drug Administration (FDA) for malignant pleural mesothelioma and more recently for metastatic nonsquamous, nonsmall cell lung cancers. As cancer patients may be treated with multiple concomitant therapies, understanding specific dermatologic adverse effects (dAEs) associated with a particular agent or class can help identify and modify the appropriate culprit. Pemetrexed, like most anti-cancer agents, has been reported to cause diverse dAEs, including alopecia, edema, erythema, urticarial vasculitis, acute generalized exanthematous pustulosis, radiation recall dermatitis, toxic epidermal necrolysis, pityriasis lichenoides-like dermatitis, and pseudocellulitis.